ERBB3 and breast carcinoma: In addition, novel therapies—e.g., patritumab deruxtecan, a novel HER3-directed ADC that has exhibited in vitro activity against ERBB3 mutations in breast cancer models (12)—will require exploration of informative biomarkers.